Conditions: Skin Diseases, Infectious
Keywords: Methicillin Resistant Staphylococcus Aureus, Skin and soft tissue infection, Bacteremia, Tedizolid
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 125
Healthy volunteers: no

Brief summary:
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).

Detailed description:

Arms:
arm 1: Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO)) arm 2: Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))

Interventions: intervention 1: Tedizolid Phosphate (Sivextro, BAY1192631) intervention 2: Linezolid
Intervention descriptions: intervention 1: BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia. intervention 2: Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

Protocol document: